<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106686</url>
  </required_header>
  <id_info>
    <org_study_id>2021-029-HR</org_study_id>
    <nct_id>NCT05106686</nct_id>
  </id_info>
  <brief_title>Effect of Aureobasidium Pullulans Produced β-glucan on Musculoskeletal Biomarkers in Adults With Relative Sarcopenia</brief_title>
  <official_title>Effect of Aureobasidium Pullulans Produced β-glucan on Musculoskeletal Biomarkers in Adults With Relative Sarcopenia: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Yangsan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct a randomized, double-blind, placebo-controlled study to investigate&#xD;
      the effects of Aureobasidium pullulans produced β-glucan on muscle strength, muscle mass, and&#xD;
      muscle function in adults with relative sarcopenia for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A previous study has indicated that Aureobasidium pullulans produced β-glucan may increase&#xD;
      muscle mass and strength. Therefore, the investigators conduct a randomized, double-blind,&#xD;
      placebo-controlled study to investigate the effects of Aureobasidium pullulans produced&#xD;
      β-glucan on muscle strength, muscle mass, and muscle function in adults with relative&#xD;
      sarcopenia; the safety of the compound are also evaluated. The Investigators examine the peak&#xD;
      torque/body weight at 60°/s knee extension, handgrip strength, skeletal muscle mass, physical&#xD;
      performance, and metabolic parameters at baseline, as well as after 6 and 12 weeks of&#xD;
      intervention. Eighty adults were administered either 1,000 mg of Aureobasidium pullulans&#xD;
      produced β-glucan or a placebo each day for 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle strength</measure>
    <time_frame>12 weeks</time_frame>
    <description>the peak torque at 60°/s knee extension (/kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>appendicular skeletal mass/(height x height)</measure>
    <time_frame>12 weeks</time_frame>
    <description>using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appendicular skeletal mass/weight x 100</measure>
    <time_frame>12 weeks</time_frame>
    <description>using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skeletal Muscle Mass Index/(height x height)</measure>
    <time_frame>12 weeks</time_frame>
    <description>using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of creatinine kinase (IU/L)</measure>
    <time_frame>12 weeks</time_frame>
    <description>creatinine kinase (IU/L) measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of lactate (mg/dL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>lactate (IU/L) measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimensional five levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>an index of life quality, minimum, maximum values (0, 1), higher scores mean a better outcome, which will be measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of brain-derived neurotrophic factor</measure>
    <time_frame>12 weeks</time_frame>
    <description>brain-derived neurotrophic factor (pg/mL) measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of insulin-like growth factor 1</measure>
    <time_frame>12 weeks</time_frame>
    <description>insulin-like growth factor 1 (ng/mL) measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostatic Model Assessment for Insulin Resistance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Homeostatic Model Assessment for Insulin Resistance measured at baseline and after 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Aureobasidium pullulans produced β-glucan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group takes Aureobasidium pullulans produced β-glucan for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group takes placebo for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aureobasidium pullulans produced β-glucan group</intervention_name>
    <description>Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks</description>
    <arm_group_label>Aureobasidium pullulans produced β-glucan group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo group</intervention_name>
    <description>Placebo 300 mg/day for 12 weeks</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &lt;110% of the standard lean body mass as measured using the body composition analyzer&#xD;
&#xD;
          -  Body mass index (BMI) ranging from 18.5 to 30.0 kg/m2&#xD;
&#xD;
          -  Those who have an average protein intake of 60 g or more/day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal liver or renal function (more than twice the normal upper limit of the&#xD;
             research institute)&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (&gt;160 mg/dL of fasting blood sugar)&#xD;
&#xD;
          -  History of fracture during the previous year&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;160/100 mmHg)&#xD;
&#xD;
          -  Uncontrolled thyroid diseases.&#xD;
&#xD;
          -  History of serious cerebro-cardiovascular diseases or cancer such as angina or&#xD;
             myocardial infarction within 6 months&#xD;
&#xD;
          -  History of any central bone fracture within 1 year&#xD;
&#xD;
          -  History of medication for psychiatric diseases such as severe depression,&#xD;
             schizophrenia, drug intoxication.&#xD;
&#xD;
          -  Alcohol abuser&#xD;
&#xD;
          -  Allergic reaction to Aureobasidium pullulans produced β-glucan&#xD;
&#xD;
          -  Those who participated in other drug clinical trials within 1 month from the screening&#xD;
             date.&#xD;
&#xD;
          -  Severe gastrointestinal symptoms such as heartburn and indigestion&#xD;
&#xD;
          -  Those who are pregnant, lactating, or plan to become pregnant during the clinical&#xD;
             trial&#xD;
&#xD;
          -  Those who are judged to be unsuitable by the PI for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Yeoup Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Yeoup Lee, MD, PhD</last_name>
    <phone>01091345959</phone>
    <phone_ext>055</phone_ext>
    <email>saylee@pnu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun Jun Kim, PhD</last_name>
    <phone>10-9135-4543</phone>
    <phone_ext>82</phone_ext>
    <email>kimhj@kyungnam.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeungsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Yeoup Lee, MD</last_name>
      <phone>360-1442</phone>
      <phone_ext>055</phone_ext>
      <email>saylee@pnu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hyun Jun Kim</last_name>
      <phone>10-9135-4543</phone>
      <phone_ext>82</phone_ext>
      <email>kimhj@kyungnam.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Sang Yeoup Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

